Table 2.
Clinical characteristics of ECMO/CRRT survivors vs. ECMO/RRT nonsurvivors
| Demographic/clinical variables | ECMO/CRRT survivor (n = 29) | ECMO/CRRT nonsurvivor (n = 19) | p value |
|---|---|---|---|
| Age, years* | 38.6 (18 to 63) | 42.7 (16 to 79) | 0.104 |
| Gender, male | 16 (55.2%) | 18 (94.7) | 0.001 |
| Race | |||
| Caucasian | 8 (30.8) | 8 (44.4) | 0.586 |
| Hispanic | 13 (50.0) | 8 (44.4) | |
| ECMO mode (VV) | 23 (79.3) | 13 (68.4) | 0.398 |
| SAPS2* (n = 27) | 66.5 (51 to 86) | 75.0 (27 to 92) | 0.288 |
| Oxygenation index* (n = 21) | 44.1 (20.1 to 80.8) | 40.7 (26.4 to 77.2) | 0.823 |
| Vasopressor requirement | 21 (77.8) | 14 (73.7) | 0.749 |
| ECMO indication | |||
| ARDS | 23 (79.3) | 19 (67.9) | 0.398 |
| Cardiac failure | 5 (17.2) | 13 (68.4) | 0.512 |
| KDIGO stage AKI | 0.613 | ||
| 0 | 9 (31.0) | 3 (15.7) | |
| 1 | 3 (10.3) | 2 (10.5) | |
| 2 | 6 (20.6) | 3 (15.7) | |
| 3 | 11 (37.9) | 10 (52.6)# | |
| UOP prior 24 h* | 1,229 (0 to 4,715) | 1,809 (0 to 5,488) | 0.134 |
| Diuretic use (n = 48) | 12 (44.4) | 4 (22.2) | 0.122 |
| CRRT indication volume management | 24 (82.7) | 14 (73.7) | 0.122 |
| Days requiring CRRT* | 10 (1 to 59) | 8 (1 to 24) | 0.642 |
| Initial dose, mL/kg/h* | 34.8 (11.8 to 75.3) | 37.7 (20.0 to 71.4) | 0.620 |
| 72 h net fluid balance, mL (L)* | −3,353 (−12.6 to 10) | 1,897 (−3.6 to 15.1) | 0.001 |
Data presented as n (%) and median (range/IQR).
*
Wilcoxon/KW test.
#
One nonsurvivor was ESRD at baseline.
Comparison of characteristics of ECMO + CRRT patients by mortality.
VV, venovenous; SAPS2, simplified acute physiology score; ECMO, extracorporeal membrane oxygenation; RRT, renal replacement therapy; CRRT, continuous RRT; AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcomes; IQR, interquartile range.